Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 17/20 | 0.51 |
| ▸ | CNR1 | P21554 | 15/20 | 0.51 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5559142 | 0.88 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL5557204 | 0.84 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL5559123 | 0.83 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL5557124 | 0.83 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL5553053 | 0.82 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DCFTR | |
| SCHEMBL5553052 | 0.82 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL5559155 | 0.81 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL1860711 | 0.81 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL5557057 | 0.80 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL5553033 | 0.80 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161671-A1 | 7-Azaindoles and the use thereof as therapeutic agents | BIOTIE THERAPIES GMBH (DE) | 2007-07-12 | — | — | US | claimed |
| US-7211583-B2 | 7-azaindoles and the use thereof as therapeutic agents | ELBION AG (DE) | 2007-05-01 | — | — | US | claimed |
| US-20040224971-A1 | 7-azaindoles and the use thereof as therapeutic agents | BIOTIE THERAPIES GMBH (DE) | 2004-11-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224971-A1 | 7-azaindoles and the use thereof as therapeutic agents | PDE4B, PDE4A, PDE4D | PDE4A 2/4885PDE4B 1/4885PDE4C 4/4885 |
| US-20070161671-A1 | 7-Azaindoles and the use thereof as therapeutic agents | PDE4B, PDE4A, PDE4D | PDE4A 2/4885PDE4B 1/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.